Vogt-Koyanagi-Harada disease: Diagnosis and treatments update

Current Opinion in Ophthalmology

Volumn 21, Issue 6, 2010, Pages 430-435

  Bordaberry, Marcela F ^a  

^a Santa Casa Complexo Hospitalar   (Brazil)

Author keywords

cyclosporine A; interleukin 17; optic coherent tomography; photoreceptor layer edema; Vogt Koyanagi Harada disease

Indexed keywords

ADALIMUMAB; ANTIMETABOLITE; AZATHIOPRINE; BEVACIZUMAB; CYCLOSPORIN; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 23; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRIAMCINOLONE;

DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ELECTRORETINOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDOCYANINE GREEN ANGIOGRAPHY; INFLAMMATORY DISEASE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHOTORECEPTOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TH17 CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; VOGT KOYANAGI SYNDROME;

ELECTRORETINOGRAPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHOTORECEPTOR CELLS, VERTEBRATE; TOMOGRAPHY, OPTICAL COHERENCE; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 78049256800     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32833eb78c     Document Type: Review

References (46)

1. Read R, Rao N, Cunningham E. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol 2000; 11:437-442.
2. Read R, Holland G, Rao N, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 2001; 131:647-652.
3. Meng Q, Liu X, Yang P, et al. PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome. Mol Vis 2009; 15:386-392.
4. Igniebi A, Gaafar A, Sheereen A, et al. HLA-DRB1 among patients with Vogt-Koyanagi-Harada disease in Saudi Arabia. Mol Vis 2009; 15:1876 - 1880.
5. Damico F, da Silva F, Gasparin F, Yamamoto J. New insights into Vogt-Koyanagi-Harada disease. Arq Bras Oftalmol 2009; 72:413-420.
6. Hou S, Yang P, Xie L, et al. Monocyte chemoattractant protein (MCP)-1-2518 A/G SNP in Chinese Han patients with VKH syndrome. Mol Vis 2009; 15:1537-1541.
7. Li K, Yang P, Zhao M, et al. Polymorphisms of FCRL3 in Chinese population with Vogt-Koyanagi-Harada (VKH) syndrome. Mol Vis 2009; 15:955-961.
8. da Silva F, Damico F, Marin M, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: considerations on the different disease categories. Am J Ophthalmol 2009; 147:339-345.
9. Bansal R, Gupta V, Gupta A. Current approach in the diagnosis and management of panuveitis. Indian J Ophthamol 2010; 58:45-54.
10. Ruiz-Allec LC, Peñaloza-López YR, Ocaña-Plante N, et al. Peripheral and central audiologic findings in patients with Vogt-Koyanagi-Harada syndrome. Acta Otorrinolaringol Esp 2009; 60:253-259.
11. Ruiz-Allec LC, Peñaloza-López YR, Ocaña-Plante N, et al. Vestibular findings in patients with Vogt-Koyanagi-Harada syndrome. Acta Otorrinolaringol Esp 2009; 60:305-310.
12. Keino H, Goto H, Mori H, et al. Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2006; 141:1140-1141.
13. Haque WM, Mir MR, Hsu S. Vogt-Koyanagi-Harada syndrome: association with alopecia areata. Dermatol Online J 2009; 15:10.
14. Foster DJ, Green RL, Rao NA. Unilateral manifestation of the Vogt-Koyanagi-Harada syndrome in a 7-year-old child [letter]. Am J Ophthalmol 1991; 111:380-382.
15. Usui Y, Goto H, Sakai J, et al. Presumed Vogt-Koyanagi-Harada disease with unilateral ocular involvement: report of three cases. Graefes Arch Clin Exp Ophthalmol 2009; 247:1127-1132.
16. Liu X, Yang P, Lin X, et al. Inhibitory effect of cyclosporine A and corticostersoids on the production of IFN-g and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin Immunol 2009; 131:333-342.
17. Kurts C. Th17 cells: a third subset of CD4+T effector cells involved in organ-specific autoimmunity. Nephrol Dial Transplant 2007; 23:1-4.
18. Lipps J, Asim Khan M. Vogt-Koyanagi-Harada syndrome: a rheumatologic perspective. Int J Clin Rheumatol 2010; 5:255-263.
19. Ishihara K, Hangai M, Kita M, Yoshimura N. Acute Vogt-Koyanagi-Harada disease in enhanced spectral-domain optical coherence tomography. Ophthalmology 2009; 116:1799-1807.
20. Lee JE, Park SW, Lee JK, et al. Edema of the photoreceptor layer in Vogt-Koyanagi-Harada disease observed using high-resolution optical coherence tomography. Korean J Ophthalmol 2009; 23:74-79.
21. Gupta V, Gupta A, Gupta P, Sharma A. Spectral-domain cirrus optical coherence tomography of choroidal striations seen in the acute stage of Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2009; 147:148.e2-153.e2.
22. Yamaguchi Y, Otani T, Kishi S. Tomographic features of serous retinal detachment with multilobular dye pooling in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2007; 144:260-265.
23. Vasconcelos-Santos D, Sohn E, Sadda S, Rao N. Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease: fundus autofluorescence and spectral domain-optical coherence tomography findings. Retina 2010; 30:33-41.
24. Kawaguchi T, Horie S, Bouchenaki N, et al. Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. Int Ophthalmol 2010; 30:41-50.
25. Bacsal K, Su Hsien Wen D, Chee S-P. Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2008; 145:480-486.
26. Peizeng Y, Wang F, Li W, et al. Study of macular function by multifocal electroretinography inpatients with Vogt-Koyanagi-Harada Syndrome. Am J Ophthalmol 2008; 146:767-771.
27. da Silva F, Hirata CE, Olivalves E, et al. Fundus-based and electroretino-graphic strategies for stratification of late Vogt-Koyanagi-Harada disease patients. Am J Ophthalmol 2009; 148:939-945.
28. Read R, Yu F, Accorinti M, et al. Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol 2006; 142:119-124.
29. Lai T, Chan R, Chan C, Lam D. Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye 2009; 23:543-548.
30. Conti S, Kerters P. The use of intravitreal corticosteroids, evidence-based and otherwise. Curr Opin Ophthalmol 2006; 17:235-244.
31. Abu El-Asrar AM, Al-Mezaine HS, Ola MS. Changing paradigms in the treatment of diabetic retinopathy. Ocular manifestations of systemic disease. Curr Opin in Ophthalmol 2009; 20:532-538.
32. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol 2010; 21:178-183.
33. Andrade R, Muccioli C, Farah M. Intravitreal triamcinolone acetonide injection in the treatment of Vogt-Koyanagi-Harada syndrome. Arq Bras Oftalmol 2004; 67:401-406.
34. Couch SM, Bakri SJ. Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol 2009; 3:41-47.
35. Perente I, Utice CA, Cakir H, et al. Management of ocular complications of Vogt-Koyanagi-Harada syndrome. Int Ophthalmol 2009; 29:33-37.
36. Chee S, Jap A, Bacsal K. Prognostic factors of Vogt-Koyanagi-Harada disease in Singapore. Am J Ophthalmol 2009; 147:154-161.
37. Jap A, Chee S. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol 2008; 19:535-540.
38. Niccoli L, Nannini C, Cassará E, et al. Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada syndrome. Br J Ophthalmol 2009; 93:1553-1554.
39. Wang Y, Gaudio P. Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm 2008; 16:167-171.
40. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007; 18:481-486.
41. Diaz-Llopis M, Amselen L, Romero FJ, et al. Adalimumab therapy for Vogt-Koyanagi-Harada syndrome. Arch Soc Esp Oftalmol 2007; 82:131-132.
42. Rodrigues E, Farah ME, Maia M, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res 2009; 28:117-144.
43. Wu L, Evans T, Saraiva M, et al. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol 2009; 53:57-60.
44. Raffa L, Bawazeer A. Intravitreal bevacizumab injection in a 14-year-old Vogt-Koyanagi-Harada patient with choroidal neovascular membrane. Can J Ophthalmol 2009; 44:615-616.
45. Tien M, Teoh S. Treatment of Vogt-Koyanagi-Harada syndrome in pregnancy. Can J Ophthalmol 2009; 44:211-212.
46. Pasadhika S, Suhler E, Cunningham Jr E. Use of biologic agents in the treatment of uveitis. Rev Ophthalmol 2010; 17:1. http://www.revophth.com/index. asp?page=1-14572.htm. [Accessed 1 January 2010]